ClinConnect ClinConnect Logo
Search / Trial NCT00762541

Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia

Launched by CARL ZEISS MEDITEC, INC. · Sep 26, 2008

Trial Information

Current as of June 02, 2025

Completed

Keywords

Myopia Laser In Situ Keratomileusis Laser Therapy Laser Corneal Surgery Refractive Surgical Procedures Ophthalmologic Surgical Procedure Operative Surgical Procedures Therapeutics

ClinConnect Summary

LASIK has become one of the most common refractive eye procedures performed in the country. Currently the MEL 80 Excimer Laser System is approved for the elimination of myopia of less than or equal to -7.0 D with or without refractive astigmatism of less than or equal to -3.0 D, with a maximum MRSE of -7.00 D. The goal of this study is to assess the safety and effectiveness information on the treatment of moderate to high magnitudes of myopia.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Myopia \> -7.00 D to -12.00 D, and astigmatism less than or equal to -6.00 D at the spectacle plane, with a maximum MRSE ≤-12.00 D.
  • Stable refraction for at least the last twelve months, as demonstrated by a change of less than 1.00 D of the spherical equivalent during the twelve months prior to the baseline examination of the eye to be treated, documented by previous clinical records.
  • Discontinue use of contact lenses at least 2 weeks for hard contacts and 3 days for soft lenses prior to the preoperative examination.
  • Hard contact lens wearers must have two central keratometry readings and two manifest refractions taken at least one week apart that do not differ by more than 0.50 D.
  • Visual acuity correctable to at least 20/40 in both eyes.
  • UCVA of 20/40 or worse in the operative eye.
  • At least 18 years of age.
  • Operative eye must be targeted for emmetropia.
  • Have a normal corneal topography.
  • Willing and able to return for scheduled follow up examinations for twelve months after surgery.
  • Sign and be given a copy of the written Informed Consent form.
  • Exclusion Criteria:
  • History of anterior segment pathology, including cataracts (in the operative eye).
  • Clinically significant dry eye syndrome unresolved by treatment.
  • Residual, recurrent, active ocular or uncontrolled eyelid disease, corneal scars within the ablation zone or other corneal abnormality such as recurrent corneal erosion or severe basement membrane disease.
  • Ophthalmoscopic signs of progressive or unstable myopia or keratoconus (or keratoconus suspect).
  • An ablation deeper than 250 microns from the corneal endothelium.
  • Irregular or unstable (distorted/not clear) corneal mires on central keratometry readings.
  • Blind in the fellow eye.
  • Undergone previous intraocular or corneal surgery of any kind in the operative eye(s), including any type of surgery for either refractive or therapeutic purposes.
  • History of ocular Herpes zoster or Herpes simplex keratitis.
  • History of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP \>21 mm Hg.
  • Must not have diabetes, diagnosed autoimmune disease, connective tissue disease, or clinically significant atopic syndrome.
  • Must not be immunocompromised or use chronic systemic corticosteroid or other immunosuppressive therapy.
  • Patients must not be pregnant, lactating, or of child-bearing potential and not practicing a medically approved method of birth control.
  • Patients must not have a known sensitivity to planned study medications.
  • Patients must not be participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation.
  • For Fellow (Second) Eyes in Simultaneous Bilateral Treatment Procedures
  • 1. Flap complications during the first eye's surgery such as a free cap, partial flap, thin flap, or irregular flap.
  • 2. Epithelial defect exceeding 2 mm x 2 mm in dimension, or clinically significant debris in the interface between the flap and underlying stroma for the first eye.
  • 3. Severe blepharospasm in the first eye that may have prevented or impeded the completion of the keratectomy and/or the laser ablation procedure.
  • 4. Poor subject cooperation with instructions for the first eye's surgery and/or poor subject fixation on the laser fixation target.
  • 5. Aborted LASIK procedure in the first eye or PRK was performed in the first eye because LASIK was not possible.

About Carl Zeiss Meditec, Inc.

Carl Zeiss Meditec, Inc. is a leading global medical technology company specializing in innovative solutions for ophthalmology and microsurgery. With a strong commitment to advancing healthcare through precision instruments and cutting-edge imaging technologies, the company develops products that enhance diagnostic capabilities and improve surgical outcomes. Leveraging decades of expertise and research, Carl Zeiss Meditec fosters collaboration with healthcare professionals to deliver high-quality clinical trials aimed at driving advancements in patient care and clinical practices within the medical field.

Locations

Greenwood Village, Colorado, United States

San Diego, California, United States

Kansas City, Missouri, United States

Eugene, Oregon, United States

Madison, Wisconsin, United States

Patients applied

0 patients applied

Trial Officials

John Doane, MD

Principal Investigator

Discover Vision Centers

Richard Hoffman, MD

Principal Investigator

Fine, Hoffman, and Packer LLC

Howard Fine, MD

Principal Investigator

Fine, Hoffman, and Packer LLC

Mark Packer, MD

Principal Investigator

FIne, Hoffman, and Packer LLC

David Tanzer, MD

Principal Investigator

US Navy Refractive Surgery Center, San Diego, CA

John Vukich, MD

Principal Investigator

Davis Duehr Dean Eye Clinic

Jon Dishler, MD

Principal Investigator

Dishler Laser Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials